<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03490331</url>
  </required_header>
  <id_info>
    <org_study_id>HTA-HG17-01</org_study_id>
    <nct_id>NCT03490331</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Assess Safety and Efficacy of Autologous Cultured Epidermal Grafts Containing Epidermal Stem Cells Genetically Modified in Patients With JEB (HOLOGENE17)</brief_title>
  <acronym>HOLOGENE17</acronym>
  <official_title>Prospective, Open-label, Uncontrolled Clinical Trial to Assess the Safety and Efficacy of Autologous Cultured Epidermal Grafts Containing Epidermal Stem Cells Genetically Modified With a Gamma-retroviral (rv) Vector Carrying COL17A1 cDNA for Restoration of Epidermis in Patients With Junctional Epidermolysis Bullosa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Holostem Terapie Avanzate s.r.l.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Paracelsus Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Holostem Terapie Avanzate s.r.l.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective open-label, uncontrolled clinical study to assess the safety and efficacy of
      autologous cultured epidermal grafts containing epidermal stem cells genetically modified
      with the aid of a gamma-retroviral vector carrying COL17A1 complementary DNA (cDNA) for
      restoration of the epidermis in patients with junctional epidermolysis bullosa. The purpose
      of this study is to demonstrate the safety and efficacy after one or more treatments with
      genetically corrected cultured epidermal autograft (Hologene 17) in patients suffering of
      junctional epidermolysis bullosa (JEB) with COL17A1 mutation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, open label, uncontrolled clinical trial, phase I/II. Patients will be
      screened according to the Study Inclusion and Exclusion criteria and will be candidate for
      the treatment if all inclusion and none of the exclusion criteria are met.

      After confirmation of eligibility, patients will undergo biopsy for the collection of the
      autologous epidermal cells to be used to produce the tissue for the treatment. In case all
      criteria are met, the transplantation of the new cultured transgenic epidermis will be
      planned according to the procedures and the need of the patient.

      The study treatment consists of a surgical intervention for new restored stem cells
      implantation.

      The surgery will be carried out in 2 stages, the first aims at taking biopsy to isolate
      epidermal cells including stem cells. The biopsy will be processed in a laboratory of a
      regenerative medicine manufacturing site where they will be corrected, expanded and prepared
      as final sheets to be implanted. Therefore, the patient can have his second intervention. In
      this second surgery, genetically corrected cultured epidermal autograft (Hologene 17) will be
      implanted into the selected area. The specialist surgeon will either use a local or general
      anaesthetic for the transplant operation. The treated area will be immobilized for some days
      after this operation. Antibiotics and anti-inflammatory drugs will be administered (if
      necessary) to prevent infections and to minimise swelling.

      Three months after the transplantation, primary endpoint will be evaluated by the
      Investigator. The study completion will be reached when 1 year (secondary endpoint) of
      follow-up after the last transplant in the last patient will be accomplished.

      The end of the trial is defined as the last visit of the last patient after the last
      treatment if any.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 19, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety events (ADRs and SAEs) related to the study treatment (tolerability)</measure>
    <time_frame>3 months after treatment</time_frame>
    <description>Number of patients experiencing treatment-related adverse events (TRAEs) - either to the epidermal graft and to the surgical procedures. Adverse events (serious and not serious) and adverse drug reactions (ADRs) will be collected and described</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety events (ADRs and SAEs) related to the study treatment (tolerability)</measure>
    <time_frame>12 months after treatment</time_frame>
    <description>Percentage of patients experiencing treatment-related adverse events (TRAEs) - either to the epidermal graft and to the surgical procedures. Adverse events (serious and not serious) and adverse drug reactions (ADRs) will be collected and described</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Skin stability in the short term (Treatment efficacy)</measure>
    <time_frame>3 months after transplantation</time_frame>
    <description>The skin stability will be evaluated by means of stripping test and visual inspection of the treated areas</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin functionality in the short term (Treatment efficacy)</measure>
    <time_frame>3 months after transplantation</time_frame>
    <description>The skin functionality will be evaluated by means of molecular testing on skin punch biopsies taken from the transplanted areas.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin stability in the long term (Treatment efficacy)</measure>
    <time_frame>12 months after transplantation</time_frame>
    <description>The skin stability will be evaluated by means of stripping test and visual inspection of the treated areas</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin functionality in the long term (Treatment efficacy)</measure>
    <time_frame>12 months after transplantation</time_frame>
    <description>The skin functionality will be evaluated by means of molecular testing on skin punch biopsies taken from the transplanted areas.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Junctional Epidermolysis Bullosa</condition>
  <arm_group>
    <arm_group_label>Genetically corrected cultured epidermal autograft</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The surgery will be carried out in 2 stages, the first aims at taking biopsy to isolate epidermal cells including stem cells. The biopsy will be processed in a laboratory of a regenerative medicine manufacturing site where they will be corrected, expanded and prepared as final sheets to be implanted.
In the second surgery, genetically corrected cultured epidermal autograft (Hologene17) will be implanted into the selected area. The specialist surgeon will either use a local or general anaesthetic for the implant operation. The treated area will be immobilized for some days after this operation. Antibiotics and anti-inflammatory drugs will be administered (if necessary) to prevent infections and to minimise swelling.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Transplantation surgery of genetically corrected cultured epidermal autograft (ATMP)</intervention_name>
    <description>Surgergical procedure for transplantation under anaesthesia of genetically corrected cultured epidermal autograft (Hologene17) on blistering skin areas of JEB patients. By taking some autologous epidermal cells, a new layer of transgenic tissue is grown in the laboratory. This layer of tissue - containing genetically modified stem cells - is then implanted by a surgeon into the damaged area. The implantation can be done in one or more areas and repeated in case of failure of the first surgery.</description>
    <arm_group_label>Genetically corrected cultured epidermal autograft</arm_group_label>
    <other_name>Transplantation of Hologene17 study product (ATMP)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed and dated informed consent prior to any study-related procedures;

          2. Male and female patients between 6 years old to 54 years old;

          3. JEB molecular characterization by mutation analysis;

          4. NC16A antibody immunofluorescence or positive staining in Western Blot analysis with
             polyclonal antibody produced against a synthetic peptide corresponding to amino acids
             131-145 of human COL17A1;

          5. Presence of chronic (persistent or recurrent for more than 3 months) large wounds (&gt;10
             cm2) and/or persistent or recurrent erosions;

          6. A cooperative attitude to follow up the study procedures (Caregivers in case of
             minors).

        Exclusion Criteria:

          1. Known or suspected intolerances against anaesthesia;

          2. Bad general condition (ECOG index &gt;1);

          3. Unresectable metastasizing Squamous Cell Carcinomas (SCCs);

          4. Antibodies to type XVII collagen associated antigens demonstrated on indirect
             immunofluorescence;

          5. Clinical and/or laboratory signs of acute systemic infections at the time of
             screening. Patient can be re-screened after appropriate treatment;

          6. Severe systemic diseases (i.e. uncompensated diabetes mellitus);

          7. Female subjects: pregnant or lactating women and all women physiologically capable of
             becoming pregnant (i.e. women of childbearing potential) UNLESS they are willing to
             use one or more reliable methods of contraception with a Pearl index â‰¤1. Reliable
             contraception should be maintained throughout the study.

          8. Allergy, sensitivity or intolerance to drugs, excipients or other material (as per
             Investigator's brochure):

               -  Transport medium (Dulbecco's Modified Eagles Medium supplemented with
                  L-glutamine)

               -  Fibrin support

               -  Povidone iodine

          9. Contraindications to the local or systemic antibiotics and/ or corticosteroids
             foreseen by the protocol;

         10. Contraindications to undergo extensive surgical procedures;

         11. Clinically significant or unstable concurrent disease or other clinical
             contraindications to stem cell transplantation based upon investigator's judgment or
             other concomitant medical conditions affecting grafting procedure;

         12. Patients (or parents in case of paediatric subject) unlikely to comply with the study
             protocol or unable to understand the nature and scope of the study or the possible
             benefits or unwanted effects of the study procedures and treatments;

         13. Participation in another clinical trial where investigational drug was received less
             than 6 months prior to screening Visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>54 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michele De Luca, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Holostem Terapie Avanzate s.r.l.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Johann W. Bauer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Paracelsus Medical University - EB House</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michele De Luca, MD</last_name>
    <phone>+390592058064</phone>
    <email>clinicaltrial@pec.holostem.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Giada Di Leo</last_name>
    <phone>+390592058747</phone>
    <email>clinicaltrial@pec.holostem.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>EB House Austria, Department of Dermatology, Paracelsus Medical University</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johann W. Bauer, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/17115047</url>
    <description>Description Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells.</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/24511464</url>
    <description>Description Long-term stability and safety of transgenic cultured epidermal stem cells in gene therapy of junctional epidermolysis bullosa.</description>
  </link>
  <link>
    <url>http://www.nature.com/articles/nature24487</url>
    <description>Regeneration of the entire human epidermis using transgenic stem cells</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/27840234</url>
    <description>Description Closure of a large chronic wound through transplantation of gene-corrected epidermal stem cells.</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2018</study_first_submitted>
  <study_first_submitted_qc>April 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2018</study_first_posted>
  <last_update_submitted>April 5, 2018</last_update_submitted>
  <last_update_submitted_qc>April 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>JEB</keyword>
  <keyword>Stem cells</keyword>
  <keyword>Gene Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epidermolysis Bullosa</mesh_term>
    <mesh_term>Epidermolysis Bullosa, Junctional</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

